PortfolioRapha Capital Management Poseida Therapeutics to Present Update on Approach in Allogeneic CAR-T at Society for Immunotherapy of Cancer 34th Annual Meeting
PortfolioRapha Capital Management NexImmune Receives IND Clearance for Phase 1/2 trial in Acute Myeloid Leukemia / Myelodysplastic Syndrome
PortfolioRapha Capital Management Poseida Therapeutics Appoints Kerry Ingalls as Chief Operating Officer
PortfolioRapha Capital Management Rapha Capital Management Participates in Series B Financing for ControlRad, Inc. Led by Questa Capital
PortfolioRapha Capital Management ControlRad Announces First Clinical Use of ControlRad Trace Radiation Reduction Technology
PortfolioRapha Capital Management AsclepiX Therapeutics Selected to Present at Ophthalmology Innovation Summit (OIS) at the American Society for Retinal Surgeons (ASRS) Annual Conference
PortfolioRapha Capital Management Bellicum Pharmaceuticals Announces Rivo-cel™ Achieves Primary Endpoint in Pediatric Registrational Trial
PortfolioRapha Capital Management Marker Therapeutics to Report Updated Results from Phase 1/2 Trial with MultiTAA Therapy in Patients with Pancreatic Adenocarcinoma
PortfolioRapha Capital Management ControlRad™ Announces FDA Clearance and Launch of the Only Radiation Reduction Technology that Integrates into Mobile C-arms
PortfolioRapha Capital Management Poseida Therapeutics Receives US FDA Orphan Drug Designation for P-BCMA-101 for the Treatment of Multiple Myeloma
